Effect of Intermittent Administration of hPTH(1-34) on Cortical Bone Geometry in Rats Treated with High-Dose Glucocorticoids

10.4077/CJP.2014.BAC242

Jun Iwamoto；Azusa Seki；Yoshihiro Sato

bone histomorphometry ； cortical bone ； glucocorticoid ； hPTH(1-34)

The Chinese Journal of Physiology

57卷5期（2014 / 10 / 31）

231 - 237

英文

High-dose glucocorticoids reduce cortical bone gain in rats. The aim of the present study was to examine the effect of the intermittent administration of human parathyroid hormone (1-34) (hPTH[1-34]) on cortical bone in rats treated with high-dose prednisolone (PSL). Twenty-five female Sprague-Dawley rats (6 weeks old) were randomized into the following three groups: a vehicle administration (control) group, a PSL (10 mg/kg s.c., 5 times a week) administration group, and a PSL + hPTH(1-34) (30 μg/kg s.c., 3 times a week) administration group. After 8 weeks of treatment, the bone mineral density (BMD) of the femoral diaphysis was determined using peripheral quantitative computed tomography, and a static bone histomorphometric analysis was performed on the tibial diaphysis. PSL administration induced a decrease in the BMD of the femoral diaphysis, compared with the control group, as well as decreases in the total tissue area, cortical area, percent cortical area, and periosteal perimeter and increases in the marrow area, percent marrow area, and endocortical perimeter of the tibial diaphysis, compared with the control group. The intermittent administration of hPTH(1-34) to PSL-treated rats attenuated PSL-related changes in the BMD of the femoral diaphysis and the percent cortical area, marrow area, percent marrow area, and endocortical perimeter of the tibial diaphysis. The findings of the present study suggest that the intermittent administration of hPTH(1-34) improves cortical BMD, acts on the endocortical bone surface, and improves cortical bone geometry, in rats treated with high-dose PSL.

1. Iwamoto, J.,Seki, A.,Takeda, T.,Yamada, H.,Sato, Y.,Yeh, J.K.(2008).Effects of combined administration of alfacalcidol and rise dronate on cancellous and cortical bone mass of the tibia in glucocorticoid-treated young rats.Chinese J. Physiol,51,121-128.
   連結：
2. Arita. S.,Ikeda, S.,Sakai, A.,Okimoto, N.,Akahoshi, S.,Nagashima, M.,Nishida, A.,Ito, M.,Nakamura, T.(2004).Human parathyroid hormone (1-34) increases mass and structure of the cortical shell, with resultant increase in lumbar bone strength, in ovariectomized rats.J. Bone Miner. Metab,22,530-540.
3. Chen, M.M.,Yeh, J.K.,Aloia, J.F.,Tierney, J.M.,Sprintz, S.(1994).Effect of treadmill exercise on tibial cortical bone in aged female rats: a histomorphometry and dual energy X-ray absorptiometry study.Bone,15,313-319.
4. Compston, J.(2010).Management of glucocorticoid-induced osteoporosis.Nat. Rev. Rheumatol,6,82-8.
5. Ekenstam, E.,Stålenheim, G.,Hällgren, R.(1988).The acute effect of high dose corticosteroid treatment on serum osteocalcin.Metabolism,37,141-144.
6. Hara, K.,Kobayashi, M.,Akiyama, Y.(2002).Vitamin K2 (menatetrenone) inhibits bone loss induced by prednisolone partly through enhancement of bone formation in rats.Bone,31,575-581.
7. Hori, M.,Uzawa, T.,Morita, K.,Noda, T.,Takahashi, H.,Inoue, J.(1988).Effect of human parathyroid hormone (PTH(1-34)) on experimental osteopenia of rats induced by ovariectomy.Bone Miner,3,193-199.
8. Iwamoto, J.,Matsumoto, H.,Takeda, T.,Sato, Y.,Liu, X.,Yeh, J.K.(2008).Effects of vitamin K2 and risedronate on bone formation and resorption, osteocyte lacunar system, and porosity in the cortical bone of glucocorticoid-treated rats.Calcif. Tissue Int,83,121-128.
9. Iwamoto, J.,Matsumoto, H.,Takeda, T,Sato, Y.,Yeh, J.K.(2010).Effects of vitamin K2 on cortical and cancellous bone mass, cortical osteocyte and lacunar system, and porosity in sciatic neurectomized rats.Calcif. Tissue Int,87,254-262.
10. Iwamoto, J.,Seki, A.,Takeda, T.,Yamada, H.,Sato, Y.,Yeh, J.K.(2007).Effects of alfacalcidol on cancellous and cortical bone mass in rats treated with glucocorticoid: a bone histomorphometry study.J. Nutr. Sci. Vitaminol.,53,191-197.
11. Iwamoto, J.,Takeda, T.,Sato, Y.(2007).Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosisusefulness of alendronate and risedronate.Expert Opin. Pharmacother,8,2743-2756.
12. Iwamoto. J.,Seki, A.,Sato, Y.,Matsumoto, H.(2012).Vitamin K2 Improves renal function and increases femoral bone strength in rats with renal insufficiency.Calcif. Tissue Int,90,50-59.
13. Jan, J.S.,Wu, W.F.(2000).Acute effect of glucocorticoid treatment on serum osteocalcin levels in asthmatic children.J. Microbiol. Immunol. Infect,33,25-28.
14. Longui, C.A.(2007).Glucocorticoid therapy: minimizing side effects.J. Pediatr. (Rio J).,83(5 Suppl),163-177.
15. Moriyama, I.,Iwamoto, J.,Takeda, T.,Toyama, Y.(2002).Comparative effects of intermittent administration of human parathyroid hormone (1-34) on cancellous and cortical bone loss in tail-suspended and sciatic neurectomized young rats.J. Orthop. Sci.,7,379-385.
16. Nakamura, T.,Sugimoto, T.,Nakano, T.,Kishimoto, H.,Ito, M.,Fukunaga, M.,Hagino, H.,Sone, T.,Yoshikawa, H.,Nishizawa, Y.,Fujita, T.,Shiraki, M.(2012).Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.J. Clin. Endocrinol. Metab.,97,3097-3106.
17. Neer, R.M.,Arnaud, C.D.,Zanchetta, J.R.,Prince, R.,Gaich, G.A.,Reginster, J.Y.,Hodsman, A.B.,Eriksen, E.F.,Ish-Shalom, S.,Genant, H.K.,Wang, O.,Mitlak, B.H.(2001).Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.N. Engl. J. Med.,344,1434-1441.
18. Nielsen, H.K.,Thomsen, K.,Eriksen, E.F.,Charles, P.,Storm, T.,Mosekilde, L.(1988).The effects of high-dose glucocorticoid administration on serum bone gamma carboxyglutamic acid-containing protein, serum alkaline phosphatase and vitamin D metabolites in normal subjects.Bone Miner,4,105-113.
19. NIH Consensus Development Panel(2001).Osteoporosis prevention, diagnosis, and therapy.J. Am. Med. Assoc.,285,785-795.
20. Okimoto, N.,Tsurukami, H.,Okazaki, Y.,Nishida, S.,Sakai, A.,Ohnishi, H.,Hori, M.,Yasukawa, K.,Nakamura, T.(1998).Effects of a weekly injection of human parathyroid hormone (1-34) and withdrawal on bone mass, strength, and turnover in mature ovariectomized rats.Bone,22,523-525.
21. Reid, D.M.,Devogelaer, J.P.,Saag, K.,Roux, C.,Lau, C.S.,Reginster, J.Y.,Papanastasiou, P.,Ferreira, A.,Hartl, F.,Fashola,T.,Mesenbrink, P.,Sambrook, P.N.(2009).Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, doubledummy, randomised controlled trial..Lancet,373,1253-1263.
22. Saag, K.G.,Shane, E.,Boonen, S.,Marín, F.,Donley, D.W.,Taylor,K.A.,Dalsky, G.P.,Marcus, R.(2007).Teriparatide or alendronate in glucocorticoid-induced oosteoporosis.N. Engl. J. Med.,357,2028-2039.
23. Saag, K.G.,Zanchetta, J.R.,Devogelaer, J.P.,Adler, R.A.,Eastell,R.,See, K.,Krege, J.H.,Krohn, K.,Warner, M.R.(2009).Effects of teriparatide versus alendronate for treating glucocorticoidinduced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.Arthritis Rheum,60,3346-3355.
24. Sakai, A.,Sakata, T.,Ikeda, S.,Uchida, S.,Okazaki, R.,Norimura,T.,Hori, M.,Nakamura, T.(1999).Intermittent administration of human parathyroid hormone(1-34) prevents immobilization-related bone loss by regulating bone marrow capacity for bone cells in ddY mice.J. Bone Miner. Res.,14,1691-1699.
25. Shen, V.,Birchman, R.,Liang, X.G.,Wu, D.D.,Lindsay, R.,Dempster, D.W.(1997).Prednisolone alone, or in combination with estrogen or dietary calcium deficiency or immobilization, inhibits bone formation but does not induce bone loss in mature rats.Bone,21,345-351.
26. Uzawa, T.,Hori, M.,Ejiri, S.,Ozawa, H.(1995).Comparison of the effects of intermittent and continuous administration of human parathyroid hormone(1-34) on rat bone.Bone,16,477-484.
27. van Staa, T.P.,Leufkens, H.G.,Cooper, C.(2002).The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis.Osteoporos. Int.,13,777-787.
28. Villanueva, A.R.(1974).A bone stain for osteoid seams in fresh, unembedded, mineralized bone.Stain Technol.,49,1-8.
29. Washimi, Y.,Ito, M.,Morishima, Y.,Taguma, K.,Ojima, Y.,Uzawa,T.,Hori, M.(2007).Effect of combined human PTH(1-34) and calcitonin treatment in ovariectomized rats.Bone,41,786-793.
30. Zhang, L.,Takahashi, H.E.,Inoue, J.,Tanizawa, T.,Endo, N.,Yamamoto, N.,Hori, M.(1997).Effects of intermittent administration of low dose human PTH(1-34) on cancellous and cortical bone of lumbar vertebral bodies in adult beagles.Bone,21,501-506.